Experimental drug combo aims to shrink aggressive breast tumors before surgery
NCT ID NCT06353997
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults whose tumors are measurable by ultrasound. The main goal is to see if the combination reduces breast tumor volume by more than 30% after two treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INBRX-106 (an experimental immunotherapy that activates OX40 receptors on immune cells) combined with pembrolizumab (Keytruda, an approved immunotherapy)
What this could lead to
If successful, this combination could shrink tumors before standard treatment, potentially improving outcomes for people with triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply broadly. The combination may cause immune-related side effects or fail to improve response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ellison Institute of Technology (EITM)
RECRUITINGLos Angeles, California, 90064, United States
Contact Phone: •••-•••-••••
-
Providence Portland Cancer Institute - Franz Clinic
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
-
Providence St. Vincent Medical Center
RECRUITINGPortland, Oregon, 97225, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Swedish Cancer Institute
NOT_YET_RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-••••